(Q34124115)

31 July 2017

1 reference

title

Monoclonal antibodies in lymphoid neoplasia: principles for optimal combined therapy (English)

1 reference

31 July 2017

Maloney GD

1

1 reference

31 July 2017

publication date

1 October 2000

1 reference

31 July 2017

published in

Seminars in Hematology

1 reference

31 July 2017

volume

37

1 reference

31 July 2017

issue

4 Suppl 7

1 reference

31 July 2017

page(s)

17-26

1 reference

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

Spontaneous alteration of idiotype in a monoclonal B-cell lymphoma. Escape from detection by anti-idiotype

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

CD20: a regulator of cell-cycle progression of B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

CD20-negative relapse after (131)I-anti-CD20 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

The multichain interleukin-2 receptor: a target for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2800%2990056-8

7 January 2021

10.1016/S0037-1963(00)90056-8

Identifiers

DOI

1 reference

31 July 2017

1 reference